The Teva-Allergan deal shows why pharma mergers are booming | Fortune
Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution; Decision Prevents Approval of Teva ANDA
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival | Ctech
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Mylan (MYL) Stock Tanks After Teva Withdraws Takeover Bid - TheStreet
Teva, Mylan to jumpstart production of old malaria drug to fight coronavirus
How Mylan tried to keep Teva from selling a generic EpiPen
Teva withdraws proposal to acquire Mylan
Mylan board rejects Teva takeover bid
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva drops bid for Mylan, buys Allergan's generics unit | Pittsburgh Post-Gazette
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva Won't Let Regulators, Poison Pill Stop Its Quest for Mylan - TheStreet
Teva settles litigation with Mylan over Nuvigil - Pharmaceutical Technology
Teva Pharmaceutical Industries' quest to acquire Mylan NV could wind up in a Dutch court - Pittsburgh Business Times
Big blow for Teva as FDA approves Mylan's generic Copaxone - Globes
Valsartan recall expands to Mylan, Teva products | Fierce Pharma
Look out, Teva: Mylan's Copaxone copy has already captured serious share | Fierce Pharma
Teva drops bid for Mylan, buys Allergan's generic drug unit - Philadelphia Business Journal
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Teva Pharmaceuticals - Wikipedia
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Teva, Mylan: Desperate Times Call For Desperate Measures (NYSE:TEVA) | Seeking Alpha
Teva offers to buy Mylan in $40 billion deal | The Times of Israel
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Mylan rejects Teva takeover bid as too low | Mint
